FindTrial
Sign In

Difluoromethylornithine

DRUG5 trials

Sponsors

University of Wisconsin, Madison, Cancer Prevention Pharmaceuticals, Inc., Indiana University, Giselle Sholler, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Focus of Study: Drug Response Biomarkers, Chemoprevention, NeoplasmsLung CancerMedulloblastomaNon Small Cell Lung CancerPost-solid Organ TransplantSkin NeoplasmsType 1 Diabetes

Phase 1

DFMO in Children With Type 1 Diabetes
CompletedNCT02384889
Indiana UniversityType 1 Diabetes
Start: 2015-04-30End: 2020-01-06Updated: 2021-09-05
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
SuspendedNCT06219174
H. Lee Moffitt Cancer Center and Research InstituteLung Cancer, Non Small Cell Lung Cancer
Start: 2024-08-07End: 2029-08-01Target: 45Updated: 2026-03-06

Phase 2

Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
CompletedNCT00204789
University of Wisconsin, MadisonPost-solid Organ Transplant, Skin Neoplasms
Start: 2003-07-31End: 2007-12-31Target: 52Updated: 2019-12-16
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
WithdrawnNCT01636128
Cancer Prevention Pharmaceuticals, Inc.Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
Start: 2014-03-31End: 2016-04-30Updated: 2014-07-30
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RecruitingNCT04696029
Giselle ShollerMedulloblastoma
Start: 2021-03-29End: 2029-03-01Target: 118Updated: 2026-03-02

Related Papers

Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes
Cell Reports Medicine2023-11-0122 citations
Targeting polyamine biosynthesis to stimulate beta cell regeneration in zebrafish
Islets2020-07-2511 citations